Zafgen, Inc. (NASDAQ:ZFGN) will be issuing its quarterly earnings data on Wednesday, August 2nd. Analysts expect the company to announce earnings of ($0.52) per share for the quarter.
Zafgen (NASDAQ:ZFGN) last announced its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. On average, analysts expect Zafgen to post $-2.22 EPS for the current fiscal year and $-1.44 EPS for the next fiscal year.
Shares of Zafgen, Inc. (NASDAQ:ZFGN) opened at 3.37 on Monday. The firm’s market capitalization is $92.24 million. Zafgen, Inc. has a one year low of $2.89 and a one year high of $5.46. The stock’s 50 day moving average price is $3.59 and its 200 day moving average price is $4.13.
In other news, insider Dennis D. Kim acquired 10,000 shares of Zafgen stock in a transaction dated Tuesday, July 11th. The stock was bought at an average cost of $3.39 per share, with a total value of $33,900.00. Following the completion of the transaction, the insider now directly owns 21,443 shares of the company’s stock, valued at $72,691.77. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.20% of the stock is owned by corporate insiders.
Several research analysts have recently weighed in on the company. ValuEngine raised Zafgen from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 6th. Zacks Investment Research cut Zafgen from a “buy” rating to a “hold” rating in a research report on Saturday, May 13th. Finally, Roth Capital assumed coverage on Zafgen in a research report on Thursday, April 20th. They set a “buy” rating and a $9.00 price objective for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $24.33.
Zafgen Company Profile
Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.
Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
